Anzeige
Mehr »
Login
Dienstag, 01.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWUQ | ISIN: US28658R1068 | Ticker-Symbol:
NASDAQ
01.04.25
19:23 Uhr
1,250 US-Dollar
+0,020
+1,63 %
1-Jahres-Chart
CLIMB BIO INC Chart 1 Jahr
5-Tage-Chart
CLIMB BIO INC 5-Tage-Chart

Aktuelle News zur CLIMB BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiClimb Bio (NASDAQ:CLYM) Releases Earnings Results, Beats Estimates By $0.02 EPS1
25.03.Climb Bio, Inc. - 8-K, Current Report1
CLIMB BIO Aktie jetzt für 0€ handeln
25.03.Climb Bio, Inc.: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates486Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus...
► Artikel lesen
25.03.Climb Bio, Inc. - 10-K, Annual Report2
20.03.Climb Bio SVP Emily Pimblett verkauft Aktien im Wert von 1.570 US-Dollar2
24.02.Climb Bio, Inc.: Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer308WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished...
► Artikel lesen
10.01.Climb Bio enters licensing deal with Mabworks for CLYM116 development1
10.01.Climb Bio, Inc. - 8-K, Current Report-
09.01.Climb Bio, Inc.: Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy170Transaction Expands Climb Bio's Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically...
► Artikel lesen
19.12.24Climb Bio, Inc.: Climb Bio to be Added to the Nasdaq Biotechnology Index103WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 - Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index (Nasdaq: NBI)...
► Artikel lesen
04.12.24Leerink Partnrs Comments on Climb Bio FY2024 Earnings2
11.11.24Climb Bio names Douglas Williams as chair1
11.11.24Climb Bio, Inc.: Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board1
24.10.24Woodforest Acceptance Solutions Partners With Clym to Enhance Website Accessibility and Compliance With Consumer Privacy Regulations288Woodforest Acceptance Solutions Partners with Clym to Enhance Merchants' Compliance and Website Accessibility, Empowering Businesses to Navigate Digital Regulations Seamlessly THE WOODLANDS, TX / ACCESSWIRE...
► Artikel lesen
15.10.24Climb Bio, Inc. - 8-K, Current Report2
15.10.24Climb Bio, Inc.: Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event1
11.10.24Climb Bio präsentiert Studie zur Behandlung von Nierenerkrankungen-
11.10.24Climb Bio to present kidney disease treatment study1
11.10.24Climb Bio, Inc.: Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 20243
04.10.24Climb Bio, Inc.: Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD191
Seite:  Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1